摘要
目的探讨噻托溴铵联合福莫特罗在中重度慢性阻塞性肺疾病患者中的临床治疗效果。方法选取2014年10月~2015年10月我院诊治的80例重度慢性阻塞性肺疾病患者。随机分为对照组和试验组各40例。对照组采用福莫特罗吸入治疗,试验组在对照组基础上联合噻托溴铵治疗,比较两组临床治疗效果。结果试验组平均住院次数为0.13±0.02次、急性发作次数为0.79±0.38次,显著少于对照组的0.27±0.06次和1.20±0.64次;试验组急性发作间隔时间为190.01±35.79d,显著长于对照组的170.46±27.01d;两组患者治疗前咳嗽、咳痰、气促以及肺部音症状评分差异无统计学意义（P〉0.05）;试验组治疗后咳嗽、咳痰、气促以及肺部音症状评分,显著低于对照组。结论中重度慢性阻塞性肺疾病患者在福莫特罗吸入治疗基础上联合噻托溴铵治疗效果理想,能够提高临床疗效,促进患者早期恢复,值得推广应用。
Objective To investigate tiotropium combined with formoterol clinical outcomes in patients with moderate to severe chronic obstructive pulmonary disease. Methods 80 cases of patients with severe chronic obstructive pulmonary disease data were analyzed in our hospital from October 2014 to October 2015, were randomly divided into two groups, 40 cases of each group.The control group using formoterol inhalation therapy, the experimental group joint tiotropium treatment in the control group, based on clinical outcomes were compared.Results The mean number of hospitalizations was（0.13±0.02）, the number of acute onset（0.79±0.38）, significantly less than the control group was（0.27±0.06） and（1.20±0.64）（P〈0.05）; the experimental group acute onset interval was（190.01±35.79）d, significantly longer than the control group was（170.46±27.01）d（P〈0.05）; the former two groups of patients cough, sputum, shortness of breath and pulmonary rales symptom score difference was not statistically significant（P〉0.05）; the experimental group after treatment of cough, sputum, shortness of breath and pulmonary rales symptom score was significantly lower than the control group（P〈0.05）. Conclusion Patients with moderate to severe chronic obstructive pulmonary disease in the United formoterol inhalation over tiotropium therapy on the basis of the therapeutic effect, can improve the clinical efficacy, promote early recovery of patients, should be widely applied.
出处
《现代诊断与治疗》
CAS
2016年第9期1610-1612,共3页
Modern Diagnosis and Treatment
关键词
噻托溴铵
福莫特罗
慢性阻塞性肺疾病
Tiotropium
Formoterol
Chronic Obstructive Pulmonary Disease
